Journal Home
Search for

Volume 49, Issue 6, Pages 884-891 (December 2008)


View previous. 7 of 38 View next.

The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(−) hepatitis B infection: Association with liver disease progression. A prospective cohort study

George Zacharakis12Corresponding Author Informationemail address, John Koskinas2, Stamatia Kotsiou3, Fevronia Tzara1, Nikolaos Vafeiadis1, Menelaos Papoutselis1, Eustratios Maltezos3, Eleftherios Sivridis4, Kostantinos Papoutselis1

Received 30 March 2008; accepted 10 June 2008. published online 02 July 2008.

Background/Aims

To evaluate the fluctuating course of serum HBV-DNA levels during the natural history of chronic HBV infection in the general population of North-Eastern Greece, in association with liver disease progression.

Methods

Two hundred and sixty-three adults with chronic HBV, median 34 years of age, were randomly selected and prospectively followed-up for a maximum period of 12 years. Viral markers, liver biochemistry and physical examination were performed every 6 months, and liver biopsy/abdominal ultrasound every 2–4 years.

Results

At entry, 195/263 (76%) were HBeAg (−)/anti-HBe (+) inactive carriers: (a) almost all 195 individuals with undetectable or HBV-DNA levels <2000IU/ml had no liver disease at entry and at follow-up period by imaging or liver histology evaluation (b) only 4/195 (2%) showed HBV reactivation with HBV-DNA >2000IU/ml.

At entry, 48/263 (18%) patients were chronic HBeAg(−); (a) 1/3 patients had intermittently HBV-DNA <2000IU/ml for at least one occasion and were misclassified as inactive carriers (b) 22/48 (46%) had moderate/severe histology at entry and 5/48 (10%) showed liver disease progression during follow-up. Logistic regression analysis was used to derive OR (95%CI) for factors associated with liver disease progression.

Conclusions

Close monitoring of serum HBV-DNA levels is useful in the management of chronic HBeAg(−) patients, as associated with liver disease progression.

Associate Editor: G.K.K. Lau

1 Unit of Preventive Medicine, Social Security Institute, Alexandroupolis, Greece

2 Second Department of Internal Medicine, Athens University, School of Medicine, Hippokration General Hospital, Athens, Greece

3 B Academic Department of Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece

4 Department of Pathology, Democritus University of Thrace Medical School, Alexandroupolis, Greece

Corresponding Author InformationCorresponding author. Tel.: +30 2107774742; fax: +30 2107706871.

 Preliminary results of this study were presented at the Liver Meeting 2007 of the American Association for the Study of Liver Diseases. This study is supported by a grant from the Subprogram 5, “Quality of Life and Environment” of the European Community Project Interreg I and II .

PII: S0168-8278(08)00414-5

doi:10.1016/j.jhep.2008.06.009


View previous. 7 of 38 View next.